Related Experiment Video

Updated: Aug 18, 2026

Quantification of Colonic Stem Cell Mutations
07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

G6PD Huntsville: a new glucose-6-phosphate dehydrogenase associated with chronic hemolytic anemia

K Hall1, M T Schreeder, J T Prchal

  • 1Division of Hematology, University of Alabama, Birmingham.

Human Genetics
|May 1, 1988
PubMed

Insights

A new glucose-6-phosphate dehydrogenase (G6PD) variant, G6PD Huntsville, was identified. This unstable enzyme variant causes hemolytic anemia despite normal red cell activity.

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common genetic disorder.
  • Chronic hemolytic anemia can result from various underlying causes, including enzyme deficiencies.

Observation:

  • A novel G6PD variant, designated G6PD Huntsville, was discovered in a patient with unexplained chronic hemolytic anemia.
  • This variant exhibited normal red blood cell enzymatic activity but demonstrated instability.

Findings:

  • G6PD Huntsville possesses normal electrophoretic mobility and a biphasic, slightly alkaline pH optimum.
  • The enzyme displays abnormal kinetics with natural substrates (G6PD, NADP) and deamino NADP, but normal activity with 2-deoxy G6PD and normal NADPH inhibition.
  • The patient, a Caucasian male from Huntsville, Alabama, showed no history of episodic jaundice.

Implications:

  • G6PD Huntsville represents a unique G6PD deficiency variant with implications for understanding enzyme structure-function relationships.
  • Further research is needed to elucidate the precise molecular mechanisms leading to hemolysis in the presence of apparently normal enzyme activity.
  • This discovery highlights the importance of comprehensive G6PD enzyme characterization in diagnosing hemolytic anemias.

More Related Videos

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue02:30

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

Published on: October 24, 2025

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...